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Abstract 
 
Primary tumors originating from the spine are very complex and challenging entities to 
treat. Because of their rarity, a multicenter collaborative network is essential to shepherd 
the best research and contribute to the dissemination of the best evidence possible. Over 
the last few years, several advances have occurred in many different fields. Surgery is 
still the cornerstone of treatment in most cases. The occasional suboptimal outcomes and 
high morbidity of surgical treatment have however encouraged professionals caring for 
these patients to explore safer treatment options and alternatives or adjuncts to surgical 
treatment. A number of novel treatment strategies have emerged from the medical, 
interventional radiology, radiation oncology and molecular worlds. This has truly 
positioned primary spine tumors at the forefront of multidisciplinary care. This article 
discusses these recent advances in detail to equip the oncologic spine surgeon and their 
team to better counsel and treat these patients. Most of these advances allow for a more 
tailored, efficient and, most importantly less morbid management of primary spine 
tumors. Some of these advances are still under investigation however and evidence-based 
oncological principles should still be strongly encouraged.  
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Introduction 
 
Advances in primary spinal tumor management have been numerous in many different 
fields, reflective of the multidisciplinary approach that its treatment requires. Once 
considered incurable, primary spinal tumors are now the research focus of many 
subspecialties, both surgical and medical, all sharing one common goal: cure. Advances 
in imaging and surgical techniques allow a broader application of evidence-based 
oncologic surgical principles for tumors originating from the spine. Surgery plays a 
central role in the management of these tumors, but many non-surgical modalities are 
also becoming available to the oncologic spine surgeon and their team to better deal with 
these highly complex patients. Medical treatment, percutaneous techniques, radiation 
therapy and molecular sequencing should now all be part of the decision making process 
when treating a patient harbouring a primary spinal tumor. The low prevalence of this 
type of tumor forces us to rely on international collaborative network of spine oncology 
centers1. Over the last few years, this shared and collaborative model has allowed access 
to large volumes of patients, which not only generated, but also contributed to the 
dissemination of the best evidence to date to guide management of primary spinal tumors. 
This article will first highlight the basic principles of management of primary tumor of 
the spine and then present the most recent advances in the different domains discussed 
above.  
 
Primary spinal tumors should be managed in experienced quaternary centers with 
appropriate multidisciplinary support teams2. Performance of invasive 
morphologic diagnostic procedures outside of such a tumor center has been 
demonstrated to independently impact prognosis3. Consequently, even prior to 
having their diagnosis, these patients should be referred to centers where 
definitive care will occur. The initial management will then include local and 
systemic staging that will culminate in a well-planned, CT-guided trocar biopsy. 
Open biopsy is correlated with increased risk of local recurrence and should 
therefore be avoided2. The surgeon should ideally perform  the biopsy procedure 
since, depending on the final histology, the biopsy tract may have to be excised. 
Once the local and systemic staging are complete, and histological diagnosis 
made, the tumor can be classified using the Enneking classification4. Originally 
described in the 1980s for primary tumor of the appendicular skeleton, this 
classification remains the foundation for approaching tumors originating from the 
spine. Based on the Enneking stages, a specific surgical margin for tumor control 
is recommended5. Terminology is of utmost importance when studying primary 
spinal tumors. Inconsistencies in previous reports were in part due to variations in 
the terminology describing the resection margins. En bloc resection means an 
attempt at resecting the whole tumor in one piece, as opposed to curettage or 
piecemeal resection, which refers to a deliberate intralesional resection. However, 
on its own and without appropriate description of margins by an experienced 
musculoskeletal pathologist, “en bloc resection” has very little value. En bloc 
resection can have intralesional, marginal, wide or radical margins. Intralesional 
resection refers to a plane of dissection that has transgressed into the lesion. A 
marginal margin denotes that the dissection has been within the reactive zone or 
the pseudocapsule surrounding the tumor, as opposed to wide margins where the 
plane of dissection is within normal tissue, beyond the reactive zone. Finally, 
radical resection refers to extracompartmental resection, which is not usually 
practical in the spine. Once the appropriate margin for control has been identified, 
the Weinstein-Boriani-Biagini (WBB) classification assists surgical planning by 
establishing feasibility criteria and strategies for achieving oncologic resection6.  
 
Surgical advances 
 
Despite considerable advancements in non-surgical care, surgery still is the common 
denominator in most cases. Respecting the Enneking principles (Enneking appropriate, 
EA) is correlated with lower recurrence rates and improved survival for primary bone 
tumors7-9. Due to its rarity, very few studies however examined tumors arising from the 
spine specifically3,10-14. Moreover, most are single center retrospective studies of multiple 
different histological diagnoses. Using the collaborative effort outlined above, the AO 
Spine Knowledge Forum Tumor has conducted the largest multicenter analyses of 
diagnosis-specific primary bone tumors of the spine, providing the best available 
evidence to date on the surgical management of these tumors. They showed that 
respecting Enneking principles results in lower local recurrence (LR) rates and increased 
median survival (MS) for both osteosarcomas (LR 10 vs 44%; MS: 6.8 vs 3.7 years)15 
and chordomas of the mobile spine (LR 16 vs 46%; MS 8.4 vs 6.4years)16. Enneking 
appropriateness has furthermore been correlated with lower recurrence rates for 
chondrosarcomas (21 vs 48%, HR: 2.09)17 and sacral chordomas (HR: 2.43)18. 
Interestingly however, despite local recurrence being strongly associated with mortality, 
these 2 last studies failed to show a relationship between respecting Enneking principles 
and survival. Short median follow-up (3 years in both studies) and the retrospective 
design of these reports might be an explanation for this lack of relationship. For 
aneurysmal bone cysts, no local recurrences were observed after EA resection compared 
to 12% for intralesionally resected benign aggressive tumors19. More analyses are 
currently underway for other benign aggressive tumors.  
 
The unique anatomy of the spine and its relationship with the surrounding neural 
structures makes treatment of primary bone tumors a risky undertaking. The cost of 
achieving appropriate margins from a patient risk and impairment perspective is high. 
The importance of thorough surgical planning and multidisciplinary support cannot be 
overemphasized. Many adjuncts have also proven to be useful to reduce the morbidity of 
surgery. Surgical navigation can decrease injury to vital structures and allow for tumor 
free osteotomy cuts, which may further improve the rate of EA surgery20. Wound 
problems are among the most prevalent adverse events after these morbid interventions. 
Vancomycin powder21, negative pressure wound therapy22 and assistance from the plastic 
surgery team23 are all key principles to decrease adverse events in this patient population. 
 
Medical and percutaneous advances 
 
Of the most meaningful recent advances in primary spinal oncology, non-surgical 
treatment of primary benign spine tumors is worth a mention. Despite their benign 
histology, some benign tumors may have an aggressive behaviour and be associated with 
undesirable outcomes even with appropriate oncologic resections. Moreover, considering 
the benign nature of some of these tumors, it might be unacceptable to inflict irreversible 
neurological deficit that an Enneking appropriate resection would command. Until 
recently, there were however no other suitable options and surgical resection was the 
mainstay of treatment. Alternative therapies are now emerging that offer promising 
outcomes, with potentially  less morbidity. 
 
In 2009, the Spine Oncology Study Group recommended en bloc resection for sacral and 
mobile spine giant cell tumors (GCT) when deemed feasible based on staging 24. Since 
then however a new medical option has arisen. Multinucleated giant cells found in GCT 
have been found to express high levels of an essential mediator in bone resorption: 
RANKL. The use of Denosumab, a monoclonal antibody that specifically inhibits 
RANKL, has been correlated with good disease control and allows for less morbid 
surgery and may even allow the avoidance of surgery in some cases25-27. Goldschlager et 
al. reported on our initial experience with Denosumab for GCT originating from the 
spine28. Results were encouraging: all tumors showed radiologic response, and surgical 
resection was facilitated by a firmer tumor and easier dissection. This new data support 
the use of Denosumab as a neo adjuvant therapy to shrink tumors and facilitate surgical 
resection as well as in the case of inoperable GCT. Although very promising, our 
experience with this treatment modality is still limited and further studies are needed. 
Specifically, long-term effect of treatment, optimal duration of treatment and its adjuvant 
role is still uncertain (ref spine focus issue paper).  
 Aneurysmal bone cyst (ABC), another benign tumor, has traditionally been treated with 
pre-operative selective arterial embolization (SAE) followed by intralesional gross total 
resection19,24. This is however associated with a high recurrence rate29. Although en bloc 
resection is associated with an extremely low risk of recurrence, potential morbidity 
associated with this type of surgical treatment has once again led to the search for 
alternative treatment options. Among them, SAE as a stand-alone treatment has 
emerged30,31 showing initial regression and recurrence rates similar to surgical excision, 
but without surgical complications. However, multiple embolizations might be required 
(35% involved 6 SAE procedures or more) to achieve tumoral response, which raises the 
issue of radiation exposure, especially in the paediatric population in whom this type of 
tumor is prevalent. While pre-operative SAE is well accepted for this vascular tumor, 
stand-alone treatment is another treatment option to consider in selected cases of ABC 
without extensive neural element involvement or high risk of pathological fracture.  
 
Osteoid osteomas (OO) are small latent or active benign tumors that will 
characteristically present with nocturnal pain and deformity in the paediatric population. 
Until recently, the gold standard treatment was surgical curettage. Percutaneous thermal 
ablation has changed the treatment paradigm for OO of the appendicular skeleton with 
failure rates as low as 5% being reported32,33. This minimally invasive treatment is now 
gaining popularity for spinal tumors showing very good results, similar to OO of the 
appendicular skeleton34. The main concern using this technique for tumors originating 
from the spine is their close vicinity to neural structures and the associated risk of thermal 
injury. In cases where there is no cortex surrounding the tumor or for tumors in close 
proximity to neural elements, thermal protection strategies such as epidural irrigation 
have been described with successful outcomes34-36.  
 
Radiation therapy advances 
 
Appropriate oncologic resection remains the gold standard when treating chordomas of 
the spine.  However, even in experienced hands, en bloc resection with marginal or wide 
margins is possible in only a  few cases (21%)37. Consequently, neo-adjuvant or adjuvant 
treatment is often necessary to increase local control. Primary malignant tumors of the 
spine are known to be radioresistant. As such, radiation doses of at least 60 to 65 Gy 
equivalents has been recommended as adjuvant treatment for chordomas and 
chondrosarcomas of the spine when there has been incomplete resection or an 
intralesional margin38. While the best radiation therapy regimen is still unknown, many 
new radiation therapy modalities and schedules of treatment are becoming available and 
are changing the treatment paradigm for these tumors. 
 
Photon-based intensity modulated radiation therapy (IMRT) is a technique that allows 3 
dimensional conformal delivery of radiation. This permits the required high dose to be 
delivered to the tumor without exceeding the safety limits that can be transmitted to the 
surrounding tissues. With advances in image guidance and radiation delivery methods, 
radiation doses that were only possible with proton beam radiotherapy can now be 
delivered with photon-based treatment, which is more widely available39-41.  
Another promising advance using photons is high-dose single fraction stereotactic 
radiosurgery. Higher doses per fraction result in more irreparable and lethal DNA 
damage, which may confer a significant biological advantage for this radioresistant 
tumor. Favourable 2-year local control rate of 95% has been reported with low morbidity 
in a heterogeneous chordoma population42. This however constitutes preliminary data and 
long-term local control from high-dose single-fraction treatment is still unknown.  
 
Proton beam radiation therapy (RT), because of its ability to deliver targeted very high 
doses of radiation while limiting dosage to surrounding tissues, has traditionally been the 
preferred option for radioresistant tumors in proximity to critical structures such as 
chordomas.  Using a combination of photons and protons (median dosage 70.2 Gy 
Relative Biological Effectiveness-RBE), 5-year local control rate as high as 94% has 
been published for primary spine sarcomas43. Recurrent disease was associated with 
worse outcomes than primary or de novo treatment. To reduce the risk of tumor seeding 
at surgery, a combination of pre and post-operative radiation treatment has moreover 
been advocated43-45. In one study, the combination of preoperative RT, en bloc resection, 
and post-operative RT boost resulted in the highest rate of local tumor control when 
compared to post-operative RT alone44. The main concern of administering pre-operative 
RT is its potential negative effect on wound healing, especially for sacral tumors. By 
limiting the accuracy of treatment, the presence of hardware is moreover correlated with 
lower local control rates, which can also be an advantage of pre-operative RT43,45,46. As 
such, multidisciplinary cooperation and discussion between surgeons and radiation 
oncologists is imperative.  
 Lastly, carbon ion therapy constitutes another promising treatment strategy. This heavy 
charged particle seems to have a biologic advantage compared with photons or protons, 
due to its increased RBE47. Excellent local control rates for chordomas have been 
reported in retrospective single center studies using this technology 48,49. One Japanese 
study reported a 5-year local control rate of 89% for unresectable sacral chordomas50. 
Even more impressive, Nishida et al. and reported better outcomes and less morbidity 
with carbon ion RT alone compared to surgery51. Although these are small series, it 
seems that carbon ion radiotherapy may be a promising alternative to surgery and that 
sacral chordomas may have the potential to be treated with radiation only.  
 
In summary, the most recent literature reveals similar LC and MS regardless of the 
radiation therapy modality used (photon, proton, carbon ion) as long as doses are 
escalated to higher levels (>70GyRBE). Studies with long-term LC rates and well defined 
toxicity profiles are underway52 and will hopefully help to answer which RT modality 
and schedule of treatment is more effective for these tumors (ref spine focus issue paper).  
 
Molecular sequencing 
 
Molecular targeted therapy is changing the way we treat cancer. Knowing the molecular 
signature of a specific tumor can lead to targeted therapy and improved outcomes. Liang 
et al. evaluated the expression of Aurora Kinase A and B in chondrosarcomas53. The ratio 
of positive expression of both the Aurora Kinase A and B was correlated with higher 
degree of invasiveness and recurrence rates. Moreover, expression of Aurora Kinase A 
was found to be an independent factor predicting poorer survival. Another group found 
that the loss of RUNX3 expression, a tumor suppressor gene, was significantly associated 
with more aggressive chondrosarcoma types and decreased survival54.  
 
The T gene is central in chordoma pathogenesis 55-57. Brachyury, the protein encoded by 
the T gene, is a transcription factor that plays a key role in the development of the 
notochord. It has been suggested that a single nucleotide polymorphism in the T gene is 
strongly linked to chordoma formation55. Although these molecular advances are still in 
their infancy, they may become important prognostic markers in the future and may form 
the basis of targeted medical therapy. It is thus crucial to prospectively analyse these 
markers and to create a collective bio bank to achieve this goal.  
 
Health related Quality of life (HRQOL) 
 
Quality of life studies are mandatory to investigate if the invasive treatment often 
required to treat primary spinal tumors is associated with acceptable quality of life for 
patients. Many articles have explored this important topic in recent years and have 
contributed to advancement in our understanding of the matter 58-62. Interestingly, studies 
with long follow-up reveal that quality of life scores improve to close to normal values 
with time. Moreover, tumor recurrence seems to be correlated with worst HRQOL than 
the invasive treatment itself59,61. Evidence-based oncologic principles should thus be 
strongly encouraged to reduce local recurrence and improve HRQOL. (ref spine focus 
issue paper)  
 
Conclusion 
 
Primary spinal tumor oncology is a very exciting field, benefitting from numerous 
important advancements over the past few years. While some of these may still be at an 
early stage, they seem very promising nonetheless. Prospective, collaborative data 
collection will hopefully shed more light on the topic and help confirm or refute novel 
treatment strategies. Until further studies are completed, we must however rely on the 
best available evidence to date and to adhere to evidence-based oncologic principles. 
Active research will hopefully lead to cure for more of these patients while reducing the 
complications of the multidisciplinary management of these patients.  
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